A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus.
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 18-1223
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers